Related Experiment Video
Updated: Apr 26, 2026
06:51
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
12.0K
Tigecycline for severe Clostridium difficile infection
Ashley Thomas1, Farhan Khan1, Nizam Uddin2
1Orlando Health, Orlando, Florida, USA.
Summary
Tigecycline shows no benefit for severe Clostridium difficile infections. Further research is required to determine if this antibiotic is effective for treating C. difficile disease.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Clostridium difficile infection (CDI) is a significant healthcare-associated pathogen.
- Limited data exist on tigecycline's efficacy in treating severe CDI.
- Tigecycline is a broad-spectrum antibiotic with activity against anaerobes.
Purpose of the Study:
- To evaluate the effectiveness of tigecycline in treating severe Clostridium difficile infection.
- To compare outcomes of severe CDI patients treated with tigecycline versus those not receiving it.
Main Methods:
- Retrospective review of patients with severe C. difficile infection.
- Comparison of clinical outcomes between tigecycline recipients and a control group.
Main Results:
- No significant difference in outcomes was observed between patients treated with tigecycline and the control group.
- Severe C. difficile infection outcomes remained similar regardless of tigecycline use.
Conclusions:
- Tigecycline does not appear to offer a benefit for severe C. difficile infections based on this study.
- Further investigation is necessary to establish tigecycline's role in managing severe CDI.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
700
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
700
01:17Drugs for Treatment of Diarrhea-Predominant IBS
999
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
999
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
689
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
689
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
2.5K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
745
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
745
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
590
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
590